Detecting the Undetectable: How Altum Sequencing Is Transforming Acute Myeloid Leukemia Monitoring
We demonstrated that our assay could detect residual disease in AML patients after treatment with 92% sensitivity and 88% specificity—a significant leap forward compared to traditional monitoring techniques.
Early relapse detection in Acute Myeloid Leukemia (AML) can make the difference between remission and recurrence. At Altum Sequencing, we've developed a game-changing, non-invasive approach to monitoring minimal residual disease (MRD) that is already showing real clinical promise.
Acute Myeloid Leukemia is a fast-moving and life-threatening blood cancer. Monitoring residual disease after treatment is critical for predicting relapses — but standard techniques like flow cytometry and qPCR often fall short, requiring painful bone marrow biopsies and lacking the sensitivity needed for early intervention.
Our tumor-informed ctDNA assay (personalized for each patient and tumor type), developed at Altum Sequencing, leverages cutting-edge next-generation sequencing (NGS) to detect MRD through a simple blood draw. This approach not only increases patient comfort, but also dramatically improves sensitivity and clinical decision-making.
In one of our latest studies published in the journal Haematologica (https://haematologica.org/article/view/8771), we demonstrated that our assay could detect residual disease in AML patients after treatment with 92% sensitivity and 88% specificity—a significant leap forward compared to traditional monitoring techniques. More importantly, our technology was able to identify patients at high risk of relapse months earlier than standard protocols.
This innovation aligns with our mission: to make precision oncology accessible and actionable. By enabling earlier and more accurate detection of relapse, Altum Sequencing’s technology offers clinicians a powerful tool to adjust treatment strategies proactively—ultimately improving survival outcomes and patient quality of life.